Skip to main content
SpringerLink
Log in

Methotrexate as an alternative to classic immunosuppressive therapies

  • Chapter
Disease-modifying Therapy in Vasculitides

Part of the book series: Progress in Inflammation Research ((PIR))

  • 52 Accesses

Abstract

The primary systemic vasculitides are a heterogeneous group of disorders which are characterized by inflammation of the blood vessel wall which may lead to compromise of the lumen and ischemia or attenuation of the vessel wall, aneurysm formation, and possible hemorrhage. Although the pathophysiology of vasculitis is not well understood, support for an immunological mechanism has come in part from the effectiveness of immunosuppressive therapy in the management of many vasculitic diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116: 488–494

    PubMed  CAS  Google Scholar 

  2. Fauci A, Haynes B, Katz P, Wolff S (1983) Wegener’s granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98: 76–85

    PubMed  CAS  Google Scholar 

  3. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124: 477–484

    PubMed  CAS  Google Scholar 

  4. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309: 1094–1104

    Article  PubMed  CAS  Google Scholar 

  5. Weinstein GD, Frost P (1971) Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 103: 33–38

    Article  PubMed  CAS  Google Scholar 

  6. Cronstein BN (1995) A novel approach to the development of anti-inflammatory agents: adenosine release at inflamed sites. J Investig Med 43: 50–57

    PubMed  CAS  Google Scholar 

  7. Cronstein BN (1996) Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 39: 1951–1960

    Article  PubMed  CAS  Google Scholar 

  8. Choy DSJ, Gould WJ, Gearhart RP (1969) Remission in Wegener’s granulomatosis treated with steroids and azathioprine. NY State J Med 69: 1205–1209

    CAS  Google Scholar 

  9. Appel GB, Gee B, Kashgarian M, Hayslett JP (1981) Wegener’s granulomatosis — clinical-pathologic correlations and long-term course. Am J Kidney Dis 1: 27–37

    PubMed  CAS  Google Scholar 

  10. Weiner SR, Paulus HE (1989) Treatment of Wegener’s granulomatosis. Semin Respir Med 10: 156–161

    Article  Google Scholar 

  11. Capizzi RL, Bertino JR (1971) Methotrexate therapy of Wegener’s granulomatosis. Ann Intern Med 74: 74–79

    PubMed  CAS  Google Scholar 

  12. Tannenbaum H (1980) Combined therapy with methotrexate and prednisone in polyarteritis nodosa. Can Med Assoc J 123: 893–894

    PubMed  CAS  Google Scholar 

  13. Fraga A, Mintz G, Orozco JH (1974) Immunosuppressive therapy in connective tissue disease other than rheumatoid arthritis. J Rheumatol 1: 374–391

    Google Scholar 

  14. Leib ES, Restino C, Paulus HE (1979) Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 67: 941–947

    Article  PubMed  CAS  Google Scholar 

  15. Mitchell MS, Gifford RH, Bertino JR, Kenney JD, Malawista SW (1976) The treatment of disseminated vasculitis with methotrexate. Inflammation 1: 285–295

    Article  Google Scholar 

  16. Espinoza LR, Espinoza CG, Vasey FB, Germain BF (1986) Oral methotrexate for chronic rheumatoid arthritis ulcerations. J Am Acad Dermatol 15: 508–512

    Article  PubMed  CAS  Google Scholar 

  17. Tiliakos N (1985) Pulse methotrexate (MTX) therapy for intractable cutaneous ulcers. Arthritis Rheum 28 (Suppl): S37

    Google Scholar 

  18. Upchurch KS, Heller K, Bress NM (1987) Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis. J Am Acad Dermatol 17: 355–359

    Article  PubMed  CAS  Google Scholar 

  19. Williams HC, Pembroke AC (1989) Methotrexate in the treatment of vasculitic cutaneous ulceration in rheumatoid arthritis. JR Soc Med 82: 763

    CAS  Google Scholar 

  20. Walton E (1958) Giant cell granuloma of the respiratory tract (Wegener’s granulomatosis). Brit Med J 2: 265–270

    Article  PubMed  CAS  Google Scholar 

  21. Hollander D, Manning RT (1967) The use of alkylating agents in the treatment of Wegener’s granulomatosis. Ann Intern Med 67: 393–398

    PubMed  CAS  Google Scholar 

  22. Fauci A, Wolff S (1973) Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine 52: 535–561

    Article  PubMed  CAS  Google Scholar 

  23. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS (1992) The treatment of Wegener’s granu-lomatosis with glucocorticoids and methotrexate. Arthritis Rheum 35: 6112–6118

    Google Scholar 

  24. Sneller M, Hoffman G, Talar-Williams C, Kerr G, Hallahan C, Fauci A (1995) Analysis of 42 Wegener’s granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38: 608–613

    Article  PubMed  CAS  Google Scholar 

  25. Langford CA, Sneller MC, Hoffman GS (1997) Methotrexate use in systemic vasculitis. Rheum Dis Clin North Am 23: 841–853

    Article  PubMed  CAS  Google Scholar 

  26. de Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL (1998) Induction of remission in Wegener’s granulomatosis with low dose methotrexate. J Rheumatol 25: 492–495

    PubMed  Google Scholar 

  27. Stone JH, Tun W, Hellman DB (1999) Treatment of non-life threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 26: 1134–1139

    PubMed  CAS  Google Scholar 

  28. de Groot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B, Gross WL (1996) Therapy for the maintenance of remission in sixty-five patients with generalized Wegen-er’s granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 39: 2052–2061

    Article  PubMed  Google Scholar 

  29. Langford CA, Talar-Williams C, Barron KS, Sneller MC (1999) A staged approach to the treatment of Wegener’s granulomatosis: induction with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 42: 2666–2673

    Article  PubMed  CAS  Google Scholar 

  30. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS (1994) Takayasu arteritis. Ann Intern Med 120: 919–929

    PubMed  CAS  Google Scholar 

  31. Hoffman GS (1996) Takayasu arteritis: lessons from the American National Institutes of Health experience. Int J Cardiol 54 (Suppl): S99–102

    Article  PubMed  Google Scholar 

  32. Hoffman GS (1995) Treatment of resistant Takayasu’s arteritis. Rheum Dis Clin North Am 21: 73–80

    PubMed  CAS  Google Scholar 

  33. Sharma BK, Sagar S, Singh AP, Suri S (1992) Takayasu arteritis in India. Heart Vessels (Suppl) 7: 37–43

    Article  CAS  Google Scholar 

  34. Sharma BK, Siveski-Iliskovic N, Singal PK (1995) Takayasu arteritis may be underdiagnosed in North America. Can J Cardiol 11: 311–316

    PubMed  CAS  Google Scholar 

  35. Morales E, Pineda C, Martinez-Lavin M (1991) Takayasu’s arteritis in children. J Rheumatol 18: 1081–1084

    PubMed  CAS  Google Scholar 

  36. Lagneau P, Michel JB, Vuong PN (1987) Surgical treatment of Takayasu’s disease. Ann Surg 205: 157–166

    Article  PubMed  CAS  Google Scholar 

  37. Hoffman GS, Ahmed AE (1998) Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol 66 (Suppl 1): S191–194; discussion S195

    Article  PubMed  Google Scholar 

  38. Giordano JM, Leavitt RY, Hoffman GS, Fauci AS (1991) Experience with surgical treatment for Takayasu’s disease. Surgery 109: 252–258

    PubMed  CAS  Google Scholar 

  39. Shelhamer JH, Volkman DJ, Parillo JE, Lawley TJ, Johnston MR, Fauci AS (1985) Takayasu’s arteritis and its therapy. Ann Intern Med 103: 121–126

    PubMed  CAS  Google Scholar 

  40. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Fauci AS (1991) Treatment of Takayasu’s arteritis with methotrexate. Arthritis Rheum. 34: S74

    Article  Google Scholar 

  41. Daina E, Schieppati A, Remuzzi G (1999) Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 130: 422–426

    PubMed  CAS  Google Scholar 

  42. Hunder GG (1997) Giant cell arteritis in polymyalgia rheumatica. Am J Med 102: 514–516

    Article  PubMed  CAS  Google Scholar 

  43. Gabriel SE, O’Fallon WM, Achkar AA, Lie JT, Hunder GG (1995) The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 22: 93–96

    PubMed  CAS  Google Scholar 

  44. Rodriguez-Valverde V, Sarabia JM, Gonzalez-Gay MA, Figueroa M, Armona J, Blanco R, Fernandez-Sueiro JL, Martinez-Taboada VM (1997) Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med 102: 331–336

    Article  PubMed  CAS  Google Scholar 

  45. Myklebust G, Gran JT (1996) A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 35: 1161–1168

    Article  PubMed  CAS  Google Scholar 

  46. Kyle V, Hazleman BL (1989) Treatment of polymyalgia rheumatic and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 48: 658–661

    Article  PubMed  CAS  Google Scholar 

  47. Ellis ME, Ralston S (1983) The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome. Ann Rheum Dis 42: 168–170

    Article  PubMed  CAS  Google Scholar 

  48. Graham E, Holland A, Avery A, Russell RW (1981) Prognosis in giant-cell arteritis. Br Med J (Clin Res Ed) 282: 269–271

    Article  CAS  Google Scholar 

  49. Evans JM, O’Fallon WM, Hunder GG (1995) Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122: 502–507

    PubMed  CAS  Google Scholar 

  50. Lie JT (1995) Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 24: 422–431

    Article  PubMed  CAS  Google Scholar 

  51. Robb-Nicholson C, Chang RW, Anderson S, Roberts WN, Longtine J, Corson J, Larson M, George D, Green J, Bryant G et al (1988) Diagnostic value of the history and examination in giant cell arteritis: a clinical pathological study of 81 temporal artery biopsies. J Rheumatol 15: 1793–1796

    PubMed  CAS  Google Scholar 

  52. Lundberg I, Hedfors E (1990) Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol 17: 1340–1345

    PubMed  CAS  Google Scholar 

  53. Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB (1988) Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens. Ann Rheum Dis 47: 733–739

    Article  PubMed  CAS  Google Scholar 

  54. Graham E, Holland A, Avery A, Russell RW (1981) Prognosis in giant-cell arteritis. Br Med J 282: 269–271

    Article  CAS  Google Scholar 

  55. Wilke WS, Hoffman GS (1995) Treatment of corticosteroid-resistant giant cell arteritis. Rheum Dis Clin North Am 21: 59–71

    PubMed  CAS  Google Scholar 

  56. Spiera RF, Mitnick H, Kupersmith MJ, Richmond M, Spiera H, Peterson M, Paget SA (1998) A prospective double-blind randomized, placebo-controlled trial of methotrexate combined with corticosteroids in the treatment of giant cell arteritis. Arthritis Rheum 41 (S): 520

    Google Scholar 

  57. van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW (1996) Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 55: 218–223

    Article  PubMed  Google Scholar 

  58. Langford CA, Klippel JH, Balow JE, James SP, Sneller MC (1998) Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann Intern Med 129: 49–58

    PubMed  CAS  Google Scholar 

  59. Goodman TA, Polisson RP (1994) Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 20: 513–528

    PubMed  CAS  Google Scholar 

  60. Furst DE (1995) Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 34 (Suppl 2): 20–25

    PubMed  Google Scholar 

  61. Sneller MC (1998) Evaluation, treatment, and prophylaxis of infections complicating systemic vasculitis. Curr Opin Rheumatol 10: 38–44

    Article  PubMed  CAS  Google Scholar 

  62. Segal BH, Sneller MC (1997) Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 23: 219–237

    Article  PubMed  CAS  Google Scholar 

  63. Govert JA, Patton S, Fine RL (1992) Pancytopenia from using trimethoprim and methotrexate. Ann Intern Med 117: 877–878

    PubMed  CAS  Google Scholar 

  64. Groenendal H, Rampen FH (1990) Methotrexate and trimethoprim-sulphamethoxazole — a potentially hazardous combination. Clin Exp Dermatol 15: 358–360

    Article  PubMed  CAS  Google Scholar 

  65. Jeurissen ME, Boerbooms AM, van de Putte LB (1989) Pancytopenia and methotrexate with trimethoprim-sulfamethoxazole. Ann Intern Med 111: 261

    PubMed  CAS  Google Scholar 

  66. Maricic M, Davis M, Gall EP (1986) Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment. Arthritis Rheum 29: 133–135

    Article  PubMed  CAS  Google Scholar 

  67. Thomas MH, Gutterman LA (1986) Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 13: 440–441

    PubMed  CAS  Google Scholar 

  68. Thomas DR, Dover JS, Camp RD (1987) Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol 17: 1055–1056

    Article  PubMed  CAS  Google Scholar 

  69. Shiroky JB (1997) The use of folates concomitantly with low-dose pulse methotrexate. Rheum Dis Clin North Am 23: 969–980

    Article  PubMed  CAS  Google Scholar 

  70. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcon GS (1994) Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 121: 833–841

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Immunologic Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA

    Carol A. Langford

  2. Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA

    Gary S. Hoffman

Authors
  1. Carol A. Langford
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary S. Hoffman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Clinical Immunology, University Hospital Groningen, P.O. Box 30.001, Groningen, 9700 RB, The Netherlands

    Cees G. M. Kallenberg

  2. Department of Clinical and Experimental Immunology, University Hospital Maastricht, P.O. Box 5800, Maastricht, 6202 AZ, The Netherlands

    Jan W. Cohen Tervaert

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Basel AG

About this chapter

Cite this chapter

Langford, C.A., Hoffman, G.S. (2001). Methotrexate as an alternative to classic immunosuppressive therapies. In: Kallenberg, C.G.M., Tervaert, J.W.C. (eds) Disease-modifying Therapy in Vasculitides. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8235-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8235-4_4

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9485-2

  • Online ISBN: 978-3-0348-8235-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation